2022
Geographic and temporal variation in racial and ethnic disparities in SARS-CoV-2 positivity between February 2020 and August 2021 in the United States
Ferguson JM, Justice AC, Osborne TF, Magid HSA, Purnell AL, Rentsch CT. Geographic and temporal variation in racial and ethnic disparities in SARS-CoV-2 positivity between February 2020 and August 2021 in the United States. Scientific Reports 2022, 12: 273. PMID: 34997001, PMCID: PMC8741774, DOI: 10.1038/s41598-021-03967-5.Peer-Reviewed Original Research
2021
Excess burden of age-associated comorbidities among people living with HIV in British Columbia, Canada: a population-based cohort study
Nanditha NGA, Paiero A, Tafessu HM, St-Jean M, McLinden T, Justice AC, Kopec J, Montaner JSG, Hogg RS, Lima VD. Excess burden of age-associated comorbidities among people living with HIV in British Columbia, Canada: a population-based cohort study. BMJ Open 2021, 11: e041734. PMID: 33419911, PMCID: PMC7799128, DOI: 10.1136/bmjopen-2020-041734.Peer-Reviewed Original ResearchConceptsHIV-negative controlsAge-associated comorbiditiesPopulation-based cohort studyCohort studyPrevalence trendsDiagnosis of comorbiditiesHIV-negative counterpartsNon-AIDS comorbiditiesHIV-negative individualsProvincial administrative databasesHIV care modelAdministrative health dataAge-associated conditionsLongitudinal cohort dataEarly ageAIDS comorbiditiesLiver diseaseEligible participantsLung diseaseAdministrative databasesHigh prevalencePLWHComorbiditiesCare modelKruskal-Wallis test
2020
Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index
King JT, Yoon JS, Rentsch CT, Tate JP, Park LS, Kidwai-Khan F, Skanderson M, Hauser RG, Jacobson DA, Erdos J, Cho K, Ramoni R, Gagnon DR, Justice AC. Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index. PLOS ONE 2020, 15: e0241825. PMID: 33175863, PMCID: PMC7657526, DOI: 10.1371/journal.pone.0241825.Peer-Reviewed Original ResearchConceptsCharlson Comorbidity IndexVeterans Health AdministrationVACO IndexValidation cohortMedical administrative dataDevelopment cohortSARS-CoV-2 testing resultsMortality indexICD-10 diagnosis codesUS Veterans Health AdministrationSARS-CoV-2 infectionPre-existing medical conditionsCOVID-19 mortality riskPeripheral vascular diseaseCOVID-19 patientsCOVID-19 infectionCOVID-19 mortalitySARS-CoV-2Administrative dataLogistic regression modelsRace/ethnicityCohort subgroupsComorbidity indexOverall mortalityComorbid conditionsEstimating Aspirin Overuse for Primary Prevention of Atherosclerotic Cardiovascular Disease (from a Nationwide Healthcare System)
Ong SY, Chui P, Bhargava A, Justice A, Hauser RG. Estimating Aspirin Overuse for Primary Prevention of Atherosclerotic Cardiovascular Disease (from a Nationwide Healthcare System). The American Journal Of Cardiology 2020, 137: 25-30. PMID: 32991852, DOI: 10.1016/j.amjcard.2020.09.042.Peer-Reviewed Original ResearchConceptsLow-dose aspirinElectronic health recordsSelf-reported useEHR dataPatients' self-reported useLow-dose aspirin useAtherosclerotic cardiovascular diseaseAmerican Heart AssociationEHR recordsNon-specific terminologyAspirin usePrimary preventionHeart AssociationCardiovascular diseaseAmerican CollegeAspirinPatientsHealth recordsEHR implementationEHR searchesImplementable guidelinesGuidelinesRecordsDiseaseCardiologyPatterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study
Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT, Skanderson M, Hauser RG, Schultze A, Jarvis CI, Holodniy M, Re V, Akgün KM, Crothers K, Taddei TH, Freiberg MS, Justice AC. Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study. PLOS Medicine 2020, 17: e1003379. PMID: 32960880, PMCID: PMC7508372, DOI: 10.1371/journal.pmed.1003379.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBetacoronavirusBlack or African AmericanClinical Laboratory TechniquesCohort StudiesCoronavirus InfectionsCOVID-19COVID-19 TestingEthnicityFemaleHispanic or LatinoHumansMaleMiddle AgedPandemicsPneumonia, ViralRetrospective StudiesSARS-CoV-2United StatesVeteransWhite PeopleYoung AdultConceptsCOVID-19 testingRace/ethnicityCohort studyWhite individualsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionAcute respiratory syndrome coronavirus 2 infectionSyndrome coronavirus 2 infectionSARS-CoV-2 infectionCOVID-19Large integrated healthcare systemCoronavirus 2 infectionNationwide cohort studyRetrospective cohort studyCoronavirus disease 2019Site of careIntegrated healthcare systemNon-Hispanic blacksPositive test resultsNon-Hispanic whitesClinical characteristicsMultivariable adjustmentComorbid conditionsMedication historyEthnic minority communitiesDisease 2019
2019
Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model
Althoff KN, Chandran A, Zhang J, Arevalo WM, Gange SJ, Sterling TR, Gill MJ, Justice AC, Palella FJ, Rebeiro PF, Silverberg MJ, Mayor AM, Horberg MA, Thorne JE, Rabkin CS, Mathews WC, Klein MB, Humes E, Lee J, Hogg R, Moore RD, Research and Design of IeDEA N. Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model. American Journal Of Epidemiology 2019, 188: 2097-2109. PMID: 31602475, PMCID: PMC7036649, DOI: 10.1093/aje/kwz232.Peer-Reviewed Original ResearchConceptsAlcohol-related deathsInjection drug useKey populationsLife expectancyDrug useHuman immunodeficiency virusLife expectancy benefitAge 20 yearsCause of deathCurrent opioid epidemicAlcohol-related mortalityAntiretroviral treatmentImmunodeficiency virusOpioid epidemicExpected life expectancyWhite womenSubstance useWhite menComparison groupDrugsDeathPLWHLife expectancy disparityMenBlack menIntegrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial
Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Deng Y, Fiellin LE, O'Connor PG, Bedimo R, Gibert CL, Marconi VC, Rimland D, Rodriguez-Barradas MC, Simberkoff MS, Tate JP, Justice AC, Bryant KJ, Fiellin DA. Integrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial. The Lancet HIV 2019, 6: e509-e517. PMID: 31109915, PMCID: PMC7161741, DOI: 10.1016/s2352-3018(19)30076-1.Peer-Reviewed Original ResearchConceptsAlcohol use disorderWeek 24Use disordersAlcohol treatmentAdverse eventsNumber of drinksTreatment medicationsPhysician managementAlcohol abuseMental Disorders-IV criteriaAlcohol-related careFormal alcohol treatmentKey exclusion criteriaTimeline followback methodMotivational enhancement therapyTreat populationHIV clinicHIV outcomesPrimary outcomeSpecialty referralsMean ageUS National InstitutesWeek 4Medical conditionsExclusion criteriaGenome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations
Kranzler HR, Zhou H, Kember RL, Vickers Smith R, Justice AC, Damrauer S, Tsao PS, Klarin D, Baras A, Reid J, Overton J, Rader DJ, Cheng Z, Tate JP, Becker WC, Concato J, Xu K, Polimanti R, Zhao H, Gelernter J. Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. Nature Communications 2019, 10: 1499. PMID: 30940813, PMCID: PMC6445072, DOI: 10.1038/s41467-019-09480-8.Peer-Reviewed Original ResearchConceptsGenome-wide association studiesAssociation studiesMillion Veteran Program sampleGenetic correlationsWide significant lociSignificant genetic correlationsPolygenic risk scoresCell type groupSignificant lociHeritable traitEnrichment analysisTraitsMultiple populationsLociPhenotypeProgram samplesAssociation of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study
Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Althoff KN, Achenbach CJ, Hessol NA, D'Souza G, Gebo KA, Gill MJ, Grover S, Horberg MA, Li J, Mathews WC, Mayor AM, Park LS, Rabkin CS, Salters K, Justice AC, Moore RD, Engels EA, Silverberg MJ, Dubrow R, AIDS N, Betts A, Brooks J, Freeman A, Van Rompaey S, Burchell A, Yip B, You B, Hogan B, Grasso C, Hogg R, Benson C, Drozd D, Sterling T, Haas D, Humes E, Crane H, Willig J, Eron J, Martin J, Saag M, Jing J, Zhang J, Lindsay J, Hunter-Mellado R, Deeks S, Zhu J, Montaner J, McReynolds J, Gabler K, Buchacz K, Rodriguez B, Thorne J, Margolick J, Anastos K, Jacobson L, Klein M, Kroch A, Morton L, Turner M, Fiellin D, Gange S, Mugavero M, Harrigan P, Rebeiro P, Bosch R, Kirk G, Mayer K, McKaig R, Coburn S, Napravnik S, Kitahata M, Lober W, Lee J. Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. The Lancet HIV 2019, 6: e240-e249. PMID: 30826282, PMCID: PMC6531288, DOI: 10.1016/s2352-3018(18)30360-6.Peer-Reviewed Original ResearchConceptsNon-Hodgkin lymphomaRecent CD4 countCD4 countHIV viraemiaKey independent predictorsViral loadIndependent predictorsNorth American AIDS Cohort CollaborationCNS non-Hodgkin's lymphomaOverall non-Hodgkin lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaAssociation of immunosuppressionMulticentre cohort studyNon-Hodgkin lymphoma (NHL) riskAverage viral loadUS Health ResourcesB-cell lymphomaOverall immune functionB cell activationLong-term careCohort CollaborationRecent immunosuppressionAntiretroviral therapyCohort studyAssociation Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test—Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder
Rentsch CT, Fiellin DA, Bryant KJ, Justice AC, Tate JP. Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test—Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder. Alcohol Clinical And Experimental Research 2019, 43: 522-530. PMID: 30620410, PMCID: PMC6397056, DOI: 10.1111/acer.13953.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAlcohol Use Disorders Identification Test-Consumption scoresAUDIT-C scoresAlcohol consumptionUnexposed patientsClinical trialsUse disordersBaseline levelsVeterans Aging Cohort StudyDoses of gabapentinAging Cohort StudyImpact of gabapentinSubstance use treatmentDifferences linear regression modelGabapentin doseCohort studyCurrent medicationsBaseline auditMultivariable differenceClinical indicationsAUD historyPatientsGabapentinClinical subpopulationsConsecutive daysContributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies
Althoff KN, Gebo KA, Moore RD, Boyd CM, Justice AC, Wong C, Lucas GM, Klein MB, Kitahata MM, Crane H, Silverberg MJ, Gill MJ, Mathews WC, Dubrow R, Horberg MA, Rabkin CS, Klein DB, Re V, Sterling TR, Desir FA, Lichtenstein K, Willig J, Rachlis AR, Kirk GD, Anastos K, Palella FJ, Thorne JE, Eron J, Jacobson LP, Napravnik S, Achenbach C, Mayor AM, Patel P, Buchacz K, Jing Y, Gange SJ, Research and Design N. Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. The Lancet HIV 2019, 6: e93-e104. PMID: 30683625, PMCID: PMC6589140, DOI: 10.1016/s2352-3018(18)30295-9.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseEnd-stage renal disease outcomesPopulation attributable fractionRenal disease outcomesTraditional risk factorsElevated total cholesterolLiver diseaseMyocardial infarctionRisk factorsRenal diseaseTotal cholesterolDisease outcomeHIV RNANorth American AIDS Cohort CollaborationDetectable plasma HIV RNALow CD4 cell countsHepatitis B virus infectionEnd-stage renal diseaseClinical AIDS diagnosisDetectable HIV RNAHIV Clinical CohortLow CD4 countCD4 cell countPlasma HIV RNAB virus infection
2018
Past year and prior incarceration and HIV transmission risk among HIV-positive men who have sex with men in the US*
Khan MR, McGinnis KA, Grov C, Scheidell JD, Hawks L, Edelman EJ, Fiellin DA, McInnes DK, Braithwaite RS, Justice AC, Wang EA. Past year and prior incarceration and HIV transmission risk among HIV-positive men who have sex with men in the US*. AIDS Care 2018, 31: 349-356. PMID: 30064277, PMCID: PMC6699634, DOI: 10.1080/09540121.2018.1499861.Peer-Reviewed Original ResearchConceptsHIV-positive MSMSex risk behaviorsViral loadSubstance useDrug useRisk behaviorsNon-injection drug useTransmission riskMultiple sex partnershipsDetectable viral loadHIV viral loadHIV transmission riskInjection drug useNew HIV infectionsHIV-positive menPrior incarcerationHealth care programsHIV infectionClinical outcomesPast yearCare programSociodemographic factorsSocial determinantsRisk determinantsMSMAssociation of Viral Suppression With Lower AIDS-Defining and Non-AIDS-Defining Cancer Incidence in HIV-Infected Veterans: A Prospective Cohort Study.
Park LS, Tate JP, Sigel K, Brown ST, Crothers K, Gibert C, Goetz MB, Rimland D, Rodriguez-Barradas MC, Bedimo RJ, Justice AC, Dubrow R. Association of Viral Suppression With Lower AIDS-Defining and Non-AIDS-Defining Cancer Incidence in HIV-Infected Veterans: A Prospective Cohort Study. Annals Of Internal Medicine 2018, 169: 87-96. PMID: 29893768, PMCID: PMC6825799, DOI: 10.7326/m16-2094.Peer-Reviewed Original ResearchConceptsLong-term viral suppressionViral suppressionLong-term suppressionCancer incidenceCancer riskHIV treatment successLow viral suppressionViral suppression statusProspective cohort studyT-cell countsEffect of CD4HIV-positive veteransCancer incidence ratesNational InstituteNational Cancer InstituteAIDS definingNon-AIDSUninfected veteransAntiretroviral therapyExcess cancer riskProspective cohortCohort studyUninfected personsIncidence rateTreatment successGender Disparities in Medical Student Research Awards
King JT, Angoff NR, Forrest JN, Justice AC. Gender Disparities in Medical Student Research Awards. Academic Medicine 2018, 93: 911-919. PMID: 29140916, DOI: 10.1097/acm.0000000000002052.Peer-Reviewed Original ResearchNonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals
Justice AC, Gordon KS, Skanderson M, Edelman EJ, Akgün KM, Gibert CL, Re V, Rimland D, Womack JA, Wyatt CM, Tate JP, Team V. Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. AIDS 2018, 32: 739-749. PMID: 29543653, PMCID: PMC5868488, DOI: 10.1097/qad.0000000000001756.Peer-Reviewed Original ResearchConceptsAdverse health outcomesHIV statusUninfected individualsVACS IndexMedication countUS Veterans Affairs Healthcare SystemHealth outcomesVeterans Affairs Healthcare SystemRisk of hospitalizationSeverity of illnessHIV-1 RNAHIV-positive individualsRisk of mortalityDose responseRace/ethnicityPolypharmacyFiscal year 2009HospitalizationMedicationsMortalityHealthcare systemAntiretroviralsOutcomesAssociationRiskHIV and Age Do Not Synergistically Affect Age-Related T-Cell Markers
Farhadian S, Jalbert E, Deng Y, Goetz MB, Park LS, Justice A, Dubrow R, Emu B. HIV and Age Do Not Synergistically Affect Age-Related T-Cell Markers. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 77: 337-344. PMID: 29140874, PMCID: PMC5807137, DOI: 10.1097/qai.0000000000001595.Peer-Reviewed Original ResearchConceptsCD8 T cellsT-cell markersCD4 T cellsHIV infectionT cellsAntiretroviral therapyEffector memory CD4 T cellsImmune systemVeterans Aging Cohort StudyMemory CD4 T cellsNaive CD4 T cellsAging Cohort StudyT cell subsetsT-cell phenotypeCopies/mLCross-sectional studyRace/ethnicityChronic HIVUninfected subjectsUninfected menCohort studyHIV diseaseHigher proportionHIV serostatusHIV status
2017
Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries
Youn B, Shireman TI, Lee Y, Galárraga O, Rana AI, Justice AC, Wilson IB. Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries. AIDS 2017, 31: 1697-1707. PMID: 28700393, PMCID: PMC5625296, DOI: 10.1097/qad.0000000000001541.Peer-Reviewed Original ResearchConceptsAngiotensin II receptor blockersII receptor blockersHIV patientsControl medicationTherapy persistenceReceptor blockersEnzyme inhibitors/angiotensin II receptor blockersCox proportional hazards modelNon-HIV medicationsUS Medicaid beneficiariesHIV-negative controlsRetrospective cohort studyKaplan-Meier curvesDuration of treatmentProportional hazards modelTen-year trendsSecular trendsART initiatorsCohort studyHazard ratioMedian timeFill dateMedicaid claimsMedicaid beneficiariesAdjusted modelCD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC)
Trickey A, May MT, Schommers P, Tate J, Ingle SM, Guest JL, Gill MJ, Zangerle R, Saag M, Reiss P, Monforte A, Johnson M, Lima VD, Sterling TR, Cavassini M, Wittkop L, Costagliola D, Sterne JAC, Boulle A, Stephan C, Miro J, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte A, del Amo J, Van Sighem A, Vehreschild J, Gill J, Guest J, Haerry D, Hogg R, Justice A, Shepherd L, Obel N, Crane H, Smith C, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Sterne J, May M, Ingle S, Trickey A. CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). Clinical Infectious Diseases 2017, 65: 959-966. PMID: 28903507, PMCID: PMC5850630, DOI: 10.1093/cid/cix466.Peer-Reviewed Original ResearchConceptsAdjusted hazard ratioCD8 countsCD8 ratioCohort CollaborationAntiretroviral therapyCause mortalityCD4 countHazard ratioMiddle tertilePrognostic markerAIDS mortalityCause-specific mortality hazard ratiosAntiretroviral Therapy Cohort CollaborationHigher CD4 countsMortality hazard ratioCells/μLHuman immunodeficiency virusIndependent prognostic markerNorth American cohortAssociation of CD8Shape of associationsAssociation of CD4Immunodeficiency virusHuman immunodeficiencyCD4Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
Collaboration T, Trickey A, May M, Vehreschild J, Obel N, Gill M, Crane H, Boesecke C, Patterson S, Grabar S, Cazanave C, Cavassini M, Shepherd L, Monforte A, van Sighem A, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice A, Sterling T, Ingle S, Sterne J. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. The Lancet HIV 2017, 4: e349-e356. PMID: 28501495, PMCID: PMC5555438, DOI: 10.1016/s2352-3018(17)30066-8.Peer-Reviewed Original ResearchConceptsInitiation of ARTAntiretroviral therapyART initiationCause mortalityHazard ratioLife expectancyCalendar periodCause-specific mortality hazard ratiosYears of ARTFirst yearHIV-1 cohortToxic antiretroviral drugsCombination antiretroviral therapyHIV-positive patientsCD4 cell countManagement of comorbiditiesMortality hazard ratioUK Medical Research CouncilHealth care plannersMedical Research CouncilEDCTP2 programmeCohort studyViral loadAntiretroviral drugsYear survivalComparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study
Caniglia EC, Cain LE, Sabin CA, Robins JM, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage GR, Bonnet F, Dabis F, Moore RD, Reiss P, van Sighem A, Mathews WC, del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Justice AC, Tate JP, Gill J, Pacheco A, Veloso VG, Bucher HC, Egger M, Furrer H, Porter K, Touloumi G, Crane H, Miro JM, Sterne JA, Costagliola D, Saag M, Hernán MA, Collaboration H, Systems C. Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. The Lancet HIV 2017, 4: e251-e259. PMID: 28411091, PMCID: PMC5492888, DOI: 10.1016/s2352-3018(17)30043-7.Peer-Reviewed Original ResearchConceptsCD4 cell countHIV-positive individualsVirological failureHazard ratioCell countViral loadRisk ratioObservational studyTime-varying CD4 cell countHIV RNA viral loadAntiretroviral therapy regimenCombination antiretroviral therapyRNA viral loadAIDS Research NetworkMortality hazard ratioIntegrated Clinical SystemsHIV-CAUSAL CollaborationLong-term safetyCell count differencesAntiretroviral therapyCD4 countTherapy regimenProspective studyImmunological outcomesClinical guidelines